December 2021 Perkins’ Head of Molecular Endocrinology and Pharmacology, Professor Kevin Pfleger, was Coincidentally, on the same day, Prof Pfleger was announced as a Fellow of the British Pharmacological Prof Pfleger has served on the ASCEPT Board since 2016 and was Chair of the Scientific Advisory Committee

Kevin Pfleger and Dr. "Congratulations to Perkins Professor Kevin Pfleger and Dr Elizabeth Johnstone who were awarded one of

A new NanoBRET® competitive binding assay 2  was developed in collaboration with Professor Kevin Pfleger Pfleger’s group in developing assays, led to two new A 2A AR tracers (CELT-463 and CELT-464) , bearing J.; Pfleger, K. D. G. Application of BRET to Monitor Ligand Binding to GPCRs.

adenocarcinoma, β-blockers and antihistamines: A clinical trial is needed Jillian G Baker ,  Erica K Sloan ,   Kevin Pfleger ,  Peter J McCormick , Cristina Salmerón ,   Paul A Insel PGxDB: an interactive web-platform

Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds

Pfleger, K.D., R.M. Seeber, and K.A.

human tissues is highly variable from more than 60 ORs in the testis and only a few ORs in the liver (Flegel

mediate ligand binding and signaling (Bannert N et al. 2001; Casarosa P et al. 2005; Gao J et al. 2003; Fieger